In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells. (2017)

Peer-Reviewed Study · S R Lai; S A Castello; A C Robinson et al. · December 2017

S R Lai et al., 2017-12: Lai et al. measure mebendazole and fenbendazole cytotoxicity in three canine glioma cell lines and show tubulin disruption on immunofluorescence; fenbendazole is roughly 18-23-fold less potent than mebendazole.

Immunofluorescence studies showed disruption of tubulin after treatment.

S R Lai et al., 2017-12: Lai et al. measure mebendazole and fenbendazole cytotoxicity in three canine glioma cell lines and show tubulin disruption on immunofluorescence; fenbendazole is roughly 18-23-fold less potent than mebendazole. Study type: canine glioma cell lines in vitro. N: not applicable. Country: USA (Auburn University College of Veterinary Medicine). Dose: fenbendazole IC50 0.550, 1.530 and 0.690 micromolar at 72 h versus mebendazole 0.030-0.080 micromolar. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: mebendazole, and primary canine fibroblasts as the normal-cell control. The potency gap between the two benzimidazoles is the useful number here. Study type: lab.